1.Observation on the effect of psychological intervention of iron combined with erythropoietin in the treatment of anemia in hemodialysis patients
Xi'er HE ; Yan-qin DING ;
Chinese Journal of Biochemical Pharmaceutics 2017;37(8):262-263,266
Objective And effect of psychological intervention observation and analysis of iron combined with erythropoietin in the treatment of anemia in hemodialysis patients and the effect of. Methods 110 cases of Shaoxing Hospital of Traditional Chinese Medicine in anemic hemodialysis patients with January 2015 to February 2016 underwent diagnosis and treatment as the research object of the study, all the patients were randomly divided into 2 groups, respectively for the test group and control group, 2 groups of 55 cases. The control group was treated with erythropoietin receptor activator and psychological intervention treatment, experimental group was treated with ferrous succinate combined with erythropoietin receptor activator for treatment, but also psychological nursing intervention, observation and comparison of the symptoms of anemia, 2 groups of patients after treatment of adverse reaction etc. Results The experimental group patients with red blood cells, serum ferritin, hemoglobin and hematocrit were significantly higher than control group, the difference was statistically significant (P<0.05); side effects in test group than in the control group, the difference was statistically significant (P<0.05). Conclusion Iron combined with erythropoietin treatment in anemic hemodialysis was more effective at the same time, then the implementation of the corresponding psychological intervention, can reduce the adverse reactions in patients with symptoms, improve the safety of the treatment, and has high applicationvalue.
2.Efficacy and safety of low molecular weight heparin combined with aspirin and urokinase in the treatment of acute myocardial infarction
Zabeer tan Gulistan ; immortals A-yi
Chinese Journal of Biochemical Pharmaceutics 2017;37(5):382-384
Objective To investigate the efficacy and safety of low molecular weight heparin combined with aspirin and urokinase in the treatment of acute myocardial infarction.MethodsEighty patients with acute myocardial infarction were randomly divided into control group and observation group.Forty patients in the first affiliated hospital of Xinjiang Medical University from January 2013 to January 2016 were randomly divided into control group and observation group.Forty patients were treated with low molecular weight heparin combined with enteric-coated aspirin;Observation group in the control group based on intravenous thrombolytic therapy.The changes of blood vessel recanalization rate, serum factor level, treatment effect and complication were observed and compared.ResultsThe levels of serum IL-6, IL-8, IL-10 and HSP70 in the two groups were significantly lower than those in the control group (P<0.05).The postoperative complications and acute mortality were significantly lower in the observation group than in the control group (P<0.05).ConclusionLow molecular weight heparin combined with aspirin and urokinase in the treatment of acute myocardial infarction can effectively improve the rate of coronary artery opening, reduce the incidence of complications, safe and reliable, worthy of clinical promotion.
3.Clinical analysis of serotretine combined with metformin in the treatment of senile diabetic patients with sulfonylurea failure
Chinese Journal of Biochemical Pharmaceutics 2017;37(7):296-298
Objective To investigate the clinical effect of sitagliptin combined with metformin in the treatment of sulfonylurea-deficient elderly patients with diabetes mellitus.Methods Sixty patients with diabetes mellitus were enrolled in our hospital from January 2013 to December 2016.The patients were divided into observation group(30 cases) and control group(30 cases) according to the random number method.The patients in the observation group were treated with sitagliptin and metformin.The patients in the control group were treated with gemcitabine, and the clinical treatment effect, fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, fasting C peptide and postprandial 2hC peptide Level of statistical comparison.Results The clinical effect of the observation group was significantly higher than that of the control group.Before and after treatment, the fasting blood glucose, 2h postprandial blood glucose, glycosylated hemoglobin, fasting C peptide and postprandial 2hC peptide level were not significantly different After fasting blood glucose, 2h postprandial blood glucose and glycosylated hemoglobin levels were significantly lower than before treatment, after treatment of fasting C peptide and postprandial 2hC peptide levels were significantly higher than before treatment.Conclusion The clinical efficacy of serotretine combined with metformin in the treatment of elderly patients with diabetes mellitus is similar to that of Yuxing, and the combination is more convenient and more suitable for clinical treatment.It is worthy to be popularized and applied in clinical practice.
4.Research progress of PARP inhibitors in ovarian cancer
Xi CHEN ; Yiming ZHU ; Tao ZHU
Chinese Journal of Biochemical Pharmaceutics 2017;37(1):319-322
Ovarian cancer is one of the highest mortality rate of gynecologic malignant tumors. Chemotherapy can improve the survival rate of the traditional ovary. In recent years, PARP [poly(ADP-ribose)polymerase]inhibitors in breast cancer susceptibility gene (breast cancer susceptibility gene, BRCA) mutations in patients with ovarian cancer can significantly improve the disease-free survival, may change the prognosis of patients with ovarian cancer. This part of PARP [poly(ADP-ribose)polymerase] inhibitors, inhibiting the repairment of DNA damage in tumor cell, causing DNA damage accumulation, eventually killing tumor cells.In breast cancer susceptibility gene 1 (breast cancer susceptibility gene1, BRCA1)/BRCA2 mutation patients with ovarian cancer, PARP inhibitors and BRCA mutation of the synthetic lethal effect provides a new direction for the development of anti-cancer drugs. Now, many highly selective and sensitive PARP inhibitors have been developed and applied in clinical trials.Although PARP inhibitor monotherapy can produce a therapeutic effect in BRCA mutation in patients with ovarian cancer, but the clinical application is still used in combination with other chemotherapy or radiotherapy. This review is focused on the recent progress in clinical trials of PARP inhibitors in combination with common chemotherapeutic agents.
5.Correlation of visfatin and L-PGDS with lower extremity arteriosclerosis
Lei XIAO ; Junhai LI ; Xiujun ZHANG
Chinese Journal of Biochemical Pharmaceutics 2017;37(1):298-301
Objective To investigate the relationship between lipocalintype prostaglandin dsynthase(L-PGDS) and visfatin in the lower extremity atherosclerotic plaque. Methods Collected from February 2014 to February 2016 in vascular surgery of our hospital 40 cases of femoral artery atherosclerotic plaque intima specimens (observation group), 20 cases of splenic artery, superior mesenteric artery samples (control group), the expression of visfatin and L-PGDS protein were detected by immunohistochemical staining, and the expression of visfatin and L-PGDS mRNA were determined by RT-PCR. Results The observation group visfatin protein expression was (121.42±11.07), significantly higher than the control group (72.07±12.81), and L-PGDS protein expression was (87.93±9.73), significantly lower than the control group (107.04±10.58), the difference was statistically significant (P<0.05). The relative expression of visfatin mRNA in the observation group was (0.321±0.024), which was significant higher than that of the control group (0.217±0.031), while L-PGDS mRNA was (0.203±0.018), significantly lower than the control group (0.314±0.029), the difference was statistically significant (P<0.05); The expression of L-PGDS protein was negatively correlated with the expression of visfatin protein in the plaque tissue (r=-0.617, P<0.05), visfatin mRNA and L-PGDS mRNA were negatively correlated (r=-0.645, P< 0.05). Conclusion Visfatin and L-PGDS in lower extremity atherosclerosis occurrence and development have an important relationship, both of them may play an antagonistic role.
6.Effect of low-dose aspirin combined with metoprolol in high blood coagulation and cardiac function of elderly patients with heart failure
Chinese Journal of Biochemical Pharmaceutics 2017;37(1):254-256
Objective To investigate the improvement role of low-dose aspirin combined with metoprolol in high blood coagulation and cardiac function of elderly patients with heart failure. Methods 112 cases of elderly patients with heart failure who were treated in our hospital from February 2014 to February 2016 were selected, these patients were randomly divided into conventional therapy group and combined treatment group (conventional therapy combined with low-dose aspirin beauty metoprolol treatment group) two groups, 56 cases in each group. Conventional therapy group was given routine treatment, combined treatment group wered treated on the basis of conventional therapy combined with metoprolol in the treatment of low-dose of aspirin. The plasma P-selectin, VWF, DD, BNP levels, HR, LVEDV, LVEF and clinical efficacy of the two groups were statistically analyzed. Results The P-selectin, VWF, DD, BNP levels of the combined treatment group were significantly lower than those in the conventional treatment group, the difference was statistically significant (P<0.05), the total treatment effective rate 89.3% (50/56) was significantly higher than the conventional therapy group 78.6% (44/56), the difference was statistically significant (P<0.05), but there was no significant difference between the two groups in HR, LVEDV, and LVEF. Conclusion Low-dose aspirin combined with metoprolol can improve the high blood coagulation and cardiac function of elderly patients with heart failure.
7.Effect of hydrochloric acid and azithromycin in the treatment of children with mycoplasma pneumonia and its effect on the level of serum inflammatory factors in children
Xingli LEI ; Zhijian LAN ; Jun XU
Chinese Journal of Biochemical Pharmaceutics 2017;37(1):248-250
Objective To investigate the effect of the treatment of children with mycoplasma pneumonia and the level of inflammatory factors in the serum of children with mycoplasma pneumonia. Methods 180 cases of mycoplasma pneumonia in our hospital from July 2015 to June 2016 were randomly divided into observation group and control group,90 cases in each group. The control group were treated with azithromycin,and the observation group were treated with combination of hydrochloric acid and bromine on the basis of control group. The course of the two groups were all 12 days.The efficacy of the treatment, fever subsided time, the disappearance time of cough and pulmonary rales, before and after treatment serum inflammatory factor interleukin-6 (IL-6),interleukin-10 (IL-10),interleukin-17 (IL-17) and procalcitonin (PCT) levels between two groups were compared,and the incidence of adverse reactions. Results The observation group treatment efficiency 93.33% was higher than the control group 82.23% (P<0.05); The observation group dissipated time of fever,cough disappeared time and pulmonary rales disappeared faster than the control group (P<0.05);After treatment,the levels of serum IL-6, IL-17 and PCT in two groups were decreased,the level of IL-10 increased,the difference was statistically significant (P<0.05); the level of serum IL-6, IL-17 and PCT in observation group were lower than the control group, while the level of IL-10 was higher than that of the control group, the difference was statistically significant (P<0.05);There were no significant differences in the adverse reactions between the two groups . Conclusion The curative effect of bromhexine hydrochloride combined with azithromycin in treatment of mycoplasma pneumonia in children, and can reduce the serum inflammatory cytokines IL-6, IL-17 and PCT level and increase the level of IL-10 and lessen inflammatory reaction, has important research significance.
8.Effects of butyphthalide on cognitive function with acute cerebral infarction complicated with leukoaraiosis
Min FEI ; Changyun CHAI ; Fei WANG
Chinese Journal of Biochemical Pharmaceutics 2017;37(1):239-241
Objective To study butylphthalide on acute cerebral infarction with leukoaraiosis patients cognitive function. Methods 80 patients with acute cerebral infarction combined with leukoaraiosis in Yuncheng Central Hospital from June 2014 to June 2015 were selected, all patients had cognitive dysfunction, and randomly divided into study group and control group with 40 cases in each group. The two groups were given conventional treatment of cerebral infarction, the study group was given the butylphthalide soft capsules two tablets, three times once day orally for three months, we used MMSE and MoCA scale to assess the cognitive status of the patients in the two groups at four, eight, and 12 weeks after treatment. The changes of liver function during treatment were analyzed. Results In the treatment, the two groups of patients with MMSE were improved, in four weeks of treatment, the MMSE scores of the study group was higher than the control group, but there was no significant difference between the two groups, eight weeks and 12 weeks, the MMSE scores of the study group was significantly higher than the control group, and the difference between the two groups was statistically significant (P<0.05), the MOCA score of patients in the study group gradually become normal, and significantly higher than the control group, after treatment for four weeks, eight weeks and 12 weeks the difference was statistically significant (P<0.05), the study group patients first had abnormal liver function in the treatment, recovered after stopping the medication. Conclusion Butylphthalide can improve the cognitive function of patients with acute cerebral infarction combined with leukoaraiosis, the increase of transaminase caused by treatment has no significant effect on clinical medication, which is worthy of further popularization and application.
9.Effect of dexamethasone combined with clomiphene on serum sex hormone levels in polycystic ovary syndrome
Meifeng XU ; Qing WEI ; Ting HE
Chinese Journal of Biochemical Pharmaceutics 2017;37(1):235-238
Objective To investigate the effect of dexamethasone combined with clomiphene on serum sex hormone levels in patients with polycystic ovary syndrome. Methods 80 pregnancies with polycystic ovary syndrome treated in our hospital from January 2013 to December 2015 were selected and they were randomly divided into observation group and control group with 40 cases in each group. The observation group was given dexamethasone combined with clomiphene, while the control group was given simple clomiphene. Compared the curative effect and the change of the levels of progesterone and estradiol before and after treatment for three months. Results After treatment, the total effective rate of the observation group was 95.00%, higher than the total effective rate of the control group was 72.50%, the difference was statistically significant (P<0.05), compared the levels of progesterone(P), estradiol(E2), luteinizing hormone(LH) and LH/FSH in the observation group and the control group, the difference was statistically significant (P<0.05), after treatment, both levels were higher than before treatment. The total ovulation rate of the observation group was 90.00%, higher than the total ovulation rate of the control group was 72.50%, the difference was statistically significant (P<0.05). The level of progesterone and estradiol in serum of polycystic ovary syndrome treated by dexamethasone combined with clomiphene had a obvious positive correlation (r=0.746, 0.812, 0.731 and 0.796, P<0.05). Conclusion Dexamethasone combined with clomiphene treatment of polycystic ovary syndrome than using only clomiphene treatment is good, which can also improve serum hormone levels in patients, effectively improve the patient's endocrine abnormalities.
10.Effect of amiodarone hydrochloride treatment time on treatment success rate of ventricular premature beats after radiofrequency ablation
Chinese Journal of Biochemical Pharmaceutics 2017;37(1):229-232
Objective To investigate the effect of treatment time with amiodarone hydrochloride on treatment success rate of ventricular premature beats after radiofrequency ablation. Methods 46 cases of patients with frequent premature ventricular arrhythmia who received RFCA for the first time in department of gardiology,huangyan hospital of wenzhou medical university from February 2013 to February 2015 were selected,and randomly divided into two groups,the control group were treated with amiodarone hydrochloride for one months,the study group were treated with amiodarone hydrochloride for six months.Left ventricular function and structural parameters,heart rate variability were measured in two groups,the main clinical symptom scores,success rate,efficacy and safety were compared. Results Compared with before treatment,two groups of LVESD,LVEDD and PVC decreased (P<0.05),LVEF increased (P<0.05),SDNN,rMSSD,PNN50,LF and HF increased (P<0.05),scores of palpitation,shortness of breath,chest tightness and main symptom score decreased (P<0.05).Compared with the control group,level of PVC in the study group was lower (P<0.05),LVEF was higher(P<0.05),LVESD and LVEDD were had no significant differences,levels of SDNN,rMSSD,PNN50,LF,HF were higher (P<0.05),scores of palpitations,shortness of breath,chest tightness main symptom score were lower (P<0.05).There were no significant differences in the success rate, clinical efficacy and adverse reaction rate between the two groups. Conclusion The time of taking amiodarone after radiofrequency catheter ablation in patients with PVCs,but taking six months and medication compared to one month,can reduce heart palpitations,chest tightness and other symptoms,and improve left ventricular function,with high security.

Result Analysis
Print
Save
E-mail